Which company develops and produces Erdafitinib?

Erdafitinib (Erdafitinib) is an oral targeted anti-cancer drug developed and produced by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, a world-renowned pharmaceutical company. As one of Johnson & Johnson's important achievements in the field of precision tumor treatment, the development background of erdafitinib is based on in-depth research on the fibroblast growth factor receptor (FGFR) pathway. The drug was initially approved by the US FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) carrying FGFR2 or FGFR3 mutations, especially for relapse or drug-resistant cases after receiving at least one platinum-containing chemotherapy regimen.

As a multinational pharmaceutical giant with a century-old history, Johnson & Johnson has an extensive pipeline of innovative drugs in multiple fields such as oncology, immunity, and neuroscience. As the core department of its innovative drug research and development, Janssen Pharmaceuticals discovered the driving role of the FGFR pathway in some tumors through target screening technology at an early stage, thus establishing the development path of erdafitinib. Thanks to its mature experience in molecular screening, clinical trial management and global registration strategies, Janssen Pharmaceuticals quickly promoted erdafitinib from the laboratory to the clinic, and received accelerated approval from the FDA in April 2019, becoming the first oral targeted drug for FGFR mutant urothelial cancer.

In addition to the U.S. market, erdafitinib was subsequently approved in many countries such as Europe and Canada. It is still in the early stage of approval or introduction in China, but with the promotion of the country’s green channel policy for the approval of rare mutation target drugs, erdafitinib is expected to officially enter the Chinese market in the near future to benefit bladder cancer patients with related gene mutations. Overall, erdafitinib not only reflects Johnson & Johnson’s scientific research strength in the field of targeted therapy, but also represents a key step in the transformation of international cancer treatment from broad-spectrum chemotherapy to precise individualization.

Reference materials：https://www.balversa.com/